VECT | VectivBio Holding AG Stock Overview

(Stock Exchange: NASDAQ)

Day's Range	N/A - N/A
52 Week Range	N/A - N/A
Beta	N/A
Implied Volatility	N/A
IV Rank	N/A
Day's Volume	N/A
Average Volume	N/A
Shares Outstanding	N/A
Market Cap	N/A
Sector	Healthcare
Industry	Biotechnology
IPO Date	2021-04-08

Valuation
Profitability
Growth
Health
P/E Ratio	N/A
Forward P/E Ratio	N/A
EPS	N/A
1YR Price Target	N/A
Dividend Yield	N/A
Dividend Per Share	N/A
Dividend ExDate	N/A
Dividend PayDate	N/A
Employees	0
Country	Switzerland
Website	VECT

VectivBio Holding AG, a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines for treatments of severe rare conditions. It develops apraglutide, a long-acting synthetic peptide analog of glucagon-like peptide-2 that is in Phase III clinical trial for the treatment of patients with short bowel syndrome-intestinal failure (SBS-IF), as well as apraglutide is in Phase II clinical trial for SBS-IF in patients with colon-in-continuity anatomy. The company is also developing apraglutide, which is in Phase II clinical trial for patients with steroid-refractory gastrointestinal acute versus host disease (aGvHD). The company was incorporated in 2019 and is headquartered in Basel, Switzerland.

VECT's peers: ABSI, ACHV, ADPT, ALLO, ALZN, ANNX, ARQT, ATRA, AUTL, CELU, CGEN, CNSP, CNTX, CRBP, IDYA, IMMP, IMRN, INKT, CYBN, ITOS, MIRM, NBTX, NBY, NERV, OMER, PHAT, PHIO, PRTG, RCUS, RIGL, RPRX, RXRX, SLNO, SPRB, TCRX, WVE, XBIT, YMAB, ZNTL, CDIO, ERNA, ZVSA, CARM

*Chart delayed

Analyzing fundamentals for VECT we got that it has weak fundamentals where Valuation is considered to be significantly overvalued, Profitability is unacceptably poor, Growth is desperately bad and Health is weak. For more detailed analysis please see VECT Fundamentals page.

Watching at VECT technicals we can see that long-term trend is bearish, the same as bearish middle-term trend, as well as bearish short-term trend. More technicals details can be found on VECT Technicals page.